Institution
Eli Lilly and Company
Company•Indianapolis, Indiana, United States•
About: Eli Lilly and Company is a company organization based out in Indianapolis, Indiana, United States. It is known for research contribution in the topics: Population & Agonist. The organization has 17826 authors who have published 22835 publications receiving 946714 citations. The organization is also known as: Eli Lily.
Topics: Population, Agonist, Insulin, Placebo, Olanzapine
Papers published on a yearly basis
Papers
More filters
••
Claude Bernard University Lyon 11, Veterans Health Administration2, McMaster University3, Eli Lilly and Company4, University of Siena5, Erasmus University Rotterdam6, Creighton University7, University of California, San Francisco8, University of Sheffield9, United States Department of Veterans Affairs10
TL;DR: Raloxifene 60 and 120 mg/d through 4 yr decreased the cumulative risk of new vertebral fractures in postmenopausal women with osteoporosis.
Abstract: The Multiple Outcomes of Raloxifene Evaluation trial studied 7705 postmenopausal women with osteoporosis randomized to placebo, or raloxifene 60 or 120 mg/d [JAMA 282(1999): 637]. This report assesses the efficacy of raloxifene on the long-term cumulative incidence new vertebral fractures through 4 yr. New vertebral fractures was assessed from radiographs taken at baseline, yr 2-4. The primary analysis was the cumulative incidence of new vertebral fractures through 4 yr. A posthoc analysis compared the vertebral fracture risk in yr 4 alone with that observed in the first 3 yr. The 4-yr cumulative relative risks (RR) for one or more new vertebral fractures were 0.64 [95% confidence interval (CI) 0.53, 0.76] with raloxifene 60 mg/d and 0.57 (95% CI 0.48, 0.69) with raloxifene 120 mg/d. In yr 4 alone, raloxifene 60 mg/d reduced the new vertebral fracture risk by 39% [RR 0.61 (95% CI 0.43, 0.88)], which was not found to be significantly different from the RR observed in the first 3 yr in both raloxifene groups, irrespective of prevalent fracture status. The nonvertebral fracture risk was not significantly reduced [RR 0.93 (95% CI 0.81, 1.06)]. The safety profile after 4 yr was similar to that observed after 3 yr. Raloxifene 60 and 120 mg/d through 4 yr decreased the cumulative risk of new vertebral fractures in postmenopausal women with osteoporosis. The decreased vertebral fracture risk in yr 4 alone was not different from that observed in the first 3 yr.
546 citations
••
TL;DR: Prasugrel 60 mg LD results in more rapid, potent, and consistent inhibition of platelet function than clopidogrel 300 mg LD and is associated with lower plasma concentrations of its active metabolite.
545 citations
•
TL;DR: dC was significantly more cytotoxic than ara-C after both 4- and 18-h incubations, suggesting that dFdC, like aRA-C, required phosphorylation by deoxycytidine kinase for biological activity.
Abstract: 2',2'-Difluorodeoxycytidine (dFdC) is a new deoxycytidine analogue with good activity against human leukemic cell lines and murine solid tumors, while the activity of 1-beta-D-arabinofuranosylcytosine (ara-C) is established in experimental systems and for the treatment of human adult leukemia. This study compared the cellular metabolism and cytotoxic properties of dFdC and ara-C in Chinese hamster ovary cells. In wild-type cells, dFdC was significantly more cytotoxic than ara-C after both 4- and 18-h incubations. The 5'-triphosphate of dFdC (dFdCTP) was the major cellular metabolite (85-90%), reaching cellular concentrations up to 20-fold greater than those observed for ara-C 5'-triphosphate at equimolar concentrations of the parent drug. A deoxycytidine kinase-deficient mutant neither accumulated dFdCTP nor showed any cytotoxic response up to drug concentrations of 100 microM. The cytotoxicity of dFdC could be competitively reversed by deoxycytidine further suggesting that dFdC, like ara-C, required phosphorylation by deoxycytidine kinase for biological activity. Several explanations for the different cellular accumulation of the drug triphosphates were established: (a) nucleoside transport studies demonstrated that the membrane permeation of dFdC was 65% more rapid than that of ara-C; (b) deoxycytidine kinase had a higher affinity for dFdC (Km = 3.6 microM) than for ara-C (Km = 8.8 microM), while the Km for deoxycytidine was 1.4 microM; (c) the elimination of intracellular dFdCTP was biphasic with t1/2 alpha = 3.9 and t1/2 beta greater than 16 h while the degradation of ara-CTP was monophasic and significantly faster (t1/2 = 0.7 h). The comparatively long half-life of dFdCTP was related to the prolonged inhibition of DNA synthesis after removal of exogenous nucleoside. Together these factors contribute to the more potent cytotoxicity of dFdC compared with ara-C.
545 citations
••
TL;DR: Using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) population, cross‐sectional relationships between amyloid deposition, hypometabolism, and cognition are examined.
Abstract: The emergence of positron emission tomography (PET) for imaging fibrillar β-amyloid (Aβ) in vivo is a critical development in the study of Alzheimer disease (AD). Recent amyloid PET studies have raised important questions about how amyloid deposition influences cognitive trajectories, particularly early in the course of disease. Determining the consequences of Aβ at different phases of disease and the relationship between Aβ and other well-known biomarkers of AD such as 18F-fluorodeoxyglucose (FDG) remain important questions that will contribute to our understanding of the clinical relevance of amyloid PET imaging and the development of effective therapies for AD.
Hypometabolism, measured with FDG-PET, is associated with cognitive decline1 and conversion from mild cognitive impairment (MCI) to AD.2,3 Recent work has demonstrated that the presence of amyloid is also associated with decline4,5 and conversion.6,7 Integrating data from a variety of sources, researchers have proposed that the time course of Aβ deposition and hypometabolism depends on disease stage,8–10 such that amyloid deposition precedes synaptic and neuronal dysfunction, which is in turn followed by cognitive decline. This model has been supported by several studies comparing the 2 PET measurements with respect to longitudinal decline,11,12 but this work has been limited by small sample sizes and access to patients at different phases of disease.
In this study, FDG-PET and amyloid PET data acquired through the Alzheimer’s Disease Neuroimaging Initiative (ADNI) made it possible to compare these measurements in a large sample at different levels of disease severity. [18F]Florbetapir is a PET ligand that has been recently added to the ADNI imaging protocol, and has been validated in a study demonstrating close correspondence between cortical amyloid deposition measured with florbetapir in end-of-life patients and immunohistochemistry measurements of fibrillar Aβ at autopsy.13
We examined cross-sectional relationships between Aβ (measured with florbetapir), hypometabolism (measured with FDG-PET), and cognitive performance (measured with the cognitive subscale of the Alzheimer’s Disease Assessment Scale [ADAS-cog]) in the ADNI population. A subset of the normal and MCI participants had retrospective longitudinal cognitive performance data available. Examining PET measurements (florbetapir, FDG) and cognitive change over time in these 2 diagnostic groups (normal, MCI) allowed us to test the hypothesis that amyloid deposition precedes hypometabolism and both are linked to longitudinal decline.
544 citations
••
TL;DR: Olanzapine demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated.
Abstract: Background We compared the efficacy and safety of olanzapine vs placebo for the treatment of acute bipolar mania Methods Four-week, randomized, double-blind, parallel study A total of 115 patients with aDSM-IVdiagnosis of bipolar disorder, manic or mixed, were randomized to olanzapine, 5 to 20 mg/d (n = 55), or placebo (n = 60) The primary efficacy measure was the Young–Mania Rating Scale (Y-MRS) total score Response and euthymia were defined, a priori, as at least a 50% improvement from baseline to end point and as a score of no less than 12 at end point in the Y-MRS total score, respectively Safety was assessed using adverse events, Extrapyramidal Symptom (EPS) rating scales, laboratory values, electrocardiograms, vital signs, and weight change Results Olanzapine-treated patients demonstrated a statistically significant greater mean (± SD) improvement in Y-MRS total score than placebo-treated patients (−148 ± 125 and −81 ± 127, respectively;P Conclusion Olanzapine demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated
542 citations
Authors
Showing all 17866 results
Name | H-index | Papers | Citations |
---|---|---|---|
Mark J. Daly | 204 | 763 | 304452 |
Irving L. Weissman | 201 | 1141 | 172504 |
Eric J. Topol | 193 | 1373 | 151025 |
Tony Hunter | 175 | 593 | 124726 |
Xiang Zhang | 154 | 1733 | 117576 |
Jerrold M. Olefsky | 143 | 595 | 77356 |
Stephen F. Badylak | 133 | 530 | 57083 |
George A. Bray | 131 | 896 | 100975 |
Lloyd Paul Aiello | 131 | 506 | 85550 |
Levi A. Garraway | 129 | 366 | 99989 |
Mark Sullivan | 126 | 802 | 63916 |
James A. Russell | 124 | 1024 | 87929 |
Tony L. Yaksh | 123 | 806 | 60898 |
Elisabetta Dejana | 122 | 430 | 48254 |
Hagop S. Akiskal | 118 | 565 | 50869 |